Immune recognition and tumor killing by cytotoxic T cells are associated with a positive outcome across multiple immunotherapies (9, 32, 38); however, the presence of neoepitope-specific CD8+ T cells in TIL-ACT remains incompletely documented outside case responders (10–15). Here, CD8A is linked to neoplasm.